The papers deserve another look too
Here are the sources behind the stories. Each note says what the source can help answer.
A link is an invitation to look closer
Did this source test the claim being made?
Read what was tested
A study in cells can explain an idea. A study in people can ask whether a treatment helps. Check which question the paper took on.
Keep the limit beside it
A trial record without results tells us what researchers set out to test. A safety page has a different job from a treatment comparison. We keep those differences in the notes below.
The source is part of the reading
You can reopen every source cited on this site here. We've kept the notes short so the papers, rather than a second retelling, are easy to find.
Retatrutide at three hormone receptors
Cell and receptor work explains the three targets. It does not test weight loss in people.
The phase 2 obesity comparison
The human weight-loss comparison also reports digestive problems and heart-rate increases. Both belong in the result.
The earlier severe-sepsis trial
The early survival finding was uncertain. Its estimate still allowed for no benefit.
The larger blinded sepsis test
The larger trial found no clear survival benefit within 28 days. It reported manufacturer funding.
Copper passing through isolated human skin
Researchers measured copper moving through skin outside the body, rather than a visible benefit in people.
Copper-peptide skincare after laser resurfacing
Thirteen people completed the comparison. Satisfaction improved; objective skin measures showed no clear difference.
MOTS-c, exercise and mouse performance
Mouse treatment findings do not establish a human treatment benefit. The exercise response is a separate observation.
Blood MOTS-c in people receiving dialysis
This study measured MOTS-c already in blood. It did not test giving anyone the peptide.
A registered human MOTS-c trial
On September 30, 2026, the registry listed a recruiting trial with a February 2026 start and no results posted. Registration alone cannot establish benefit or safety.
FDA's review of MOTS-c safety gaps
Missing human safety information and possible immune reactions are concerns, rather than observed side-effect rates.
FDA's compounding safety concerns and withdrawn nominations
The withdrawn nominations include thymosin alpha-1, MOTS-c and injectable GHK-Cu. Withdrawal isn't clearance or permission to compound.
FDA's thymosin alpha-1 safety review
The review raises concerns about impurities and clumping in injected preparations, including possible immune reactions.
FDA's concerns about unapproved weight-loss drugs
Research-use wording doesn't turn an unapproved product into an approved medicine. Compounded drugs are not FDA-approved.
FDA's separate listing for non-injectable GHK-Cu
Non-injectable GHK-Cu is in Category 1, under evaluation. The conditional interim policy is not drug approval and does not cover injected GHK-Cu.